Acute Lymphoblastic Leukemia in Children | NEJM Skip to main content NEJM Group Follow Us
Facebook Twitter Instagram YouTube LinkedIn Prepare to become a physician, build your …

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. In the past
ALL was intractable but now the survival probability is as high as 80–90%. Improved …

Administration of lymphodepletion chemotherapy followed by CD19-specific chimeric
antigen receptor (CAR)–modified T cells is a remarkably effective approach to treating …

Purpose Philadelphia chromosome (Ph)–like acute lymphoblastic leukemia (ALL) is a high-
risk subtype of childhood ALL characterized by kinase-activating alterations that are …

Acute lymphoblastic leukaemia occurs in both children and adults but its incidence peaks
between 2 and 5 years of age. Causation is multifactorial and exogenous or endogenous …

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy.
Advancements in technology that enhance our understanding of the biology of the disease …

Improved supportive care, more precise risk stratification, and personalized chemotherapy
based on the characteristics of leukemic cells and hosts (eg, pharmacokinetics and …

The 50th anniversary of Seminars in Hematology coincides with the 50th anniversary of St.
Jude Children's Research Hospital, and both milestones are inexorably linked to studies …

Background No randomised study has shown whether stratification of treatment by minimal
residual disease (MRD) response improves outcome in children and young people with …

Acute lymphoblastic leukemia (ALL) is a heterogeneous disease at the genetic level.
Chromosomal abnormalities are used as diagnostic, prognostic and predictive biomarkers to …